Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 3

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 2(4)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04736810Phase 2Completed

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT04172233Phase 1Completed

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Role: collaborator

NCT04173637Phase 2Completed

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Role: collaborator

NCT03866967Phase 2Completed

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT04172571Phase 2Completed

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Role: collaborator

NCT03866980Phase 3Terminated

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer

Role: collaborator

NCT03866993Phase 3Completed

A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer

Role: collaborator

All 7 trials loaded